- Home
- LVTX vs ANTX Comparison
LVTX vs ANTX Comparison
Compare LVTX & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LVTX
- ANTX
- Stock Information
- Founded
- LVTX 2016
- ANTX 2017
- Country
- LVTX Netherlands
- ANTX United States
- Employees
- LVTX N/A
- ANTX N/A
- Industry
- LVTX Biotechnology: Pharmaceutical Preparations
- ANTX Biotechnology: Pharmaceutical Preparations
- Sector
- LVTX Health Care
- ANTX Health Care
- Exchange
- LVTX Nasdaq
- ANTX Nasdaq
- Market Cap
- LVTX 40.0M
- ANTX 34.4M
- IPO Year
- LVTX 2021
- ANTX 2022
- Fundamental
- Price
- LVTX $1.64
- ANTX $1.09
- Analyst Decision
- LVTX Hold
- ANTX Buy
- Analyst Count
- LVTX 4
- ANTX 2
- Target Price
- LVTX $1.58
- ANTX $2.00
- AVG Volume (30 Days)
- LVTX 131.8K
- ANTX 80.4K
- Earning Date
- LVTX 11-06-2025
- ANTX 11-12-2025
- Dividend Yield
- LVTX N/A
- ANTX N/A
- EPS Growth
- LVTX N/A
- ANTX N/A
- EPS
- LVTX N/A
- ANTX N/A
- Revenue
- LVTX $4,990,000.00
- ANTX N/A
- Revenue This Year
- LVTX N/A
- ANTX N/A
- Revenue Next Year
- LVTX N/A
- ANTX N/A
- P/E Ratio
- LVTX N/A
- ANTX N/A
- Revenue Growth
- LVTX N/A
- ANTX N/A
- 52 Week Low
- LVTX $0.85
- ANTX $1.01
- 52 Week High
- LVTX $2.00
- ANTX $1.68
- Technical
- Relative Strength Index (RSI)
- LVTX 62.46
- ANTX 40.17
- Support Level
- LVTX $1.60
- ANTX $1.05
- Resistance Level
- LVTX $1.83
- ANTX $1.17
- Average True Range (ATR)
- LVTX 0.07
- ANTX 0.05
- MACD
- LVTX 0.01
- ANTX -0.00
- Stochastic Oscillator
- LVTX 65.28
- ANTX 23.81
About LVTX LAVA Therapeutics N.V.
LAVA Therapeutics NV isa clinical stage immuno-oncology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer. Company's pipeline include's products such as LAVA-1266, LAVA-1427, LAVA-1433, LAVA-1207, PF08046052, JNJ89853413.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.